PuSH - Publikationsserver des Helmholtz Zentrums München

Shi, R.* ; Bao, X* ; Rogowski, P.* ; Schäfer, C.* ; Schmidt-Hegemann, N.S.* ; Unger, K. ; Lu, S.* ; Sun, J.* ; Buchner, A.* ; Stief, C.* ; Belka, C.* ; Li, M.*

Establishment and validation of an individualized cell cycle process-related gene signature to predict cancer-specific survival in patients with bladder cancer.

Cancers 12:1146 (2020)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
More accurate models are essential to identify high-risk bladder cancer (BCa) patients who will benefit from adjuvant therapies and thus helpful to facilitate personalized management of BCa. Among various cancer-related hallmarks and pathways, cell cycle process (CCP) was identified as a dominant risk factor for cancer-specific survival (CSS) in BCa. Using a series of bioinformatic and statistical approaches, a CCP-related gene signature was established, and the prognostic value was validated in other independent BCa cohorts. In addition, the risk score derived from the gene signature serves as a promising marker for therapeutic resistance. In combination with clinicopathological features, a nomogram was constructed to provide more accurate prediction for CSS, and a decision tree was built to identify high-risk subgroup of muscle invasive BCa patients. Overall, the gene signature could be a useful tool to predict CSS and help to identify high-risk subgroup of BCa patients, which may benefit from intensified adjuvant therapy.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Bladder Cancer ; Cell Cycle Process ; Gene Signature ; Cancer-specific Survival ; Therapeutic Resistance; Poor-prognosis; Progression; Wdr62; Overexpression; Activation; Discovery; Genomics; Ccnd1; Rce1
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 12, Heft: 5, Seiten: , Artikelnummer: 1146 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Translational Metabolic Oncology (TMO)